MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574779 | Name: Meloxicam sodium salt hydrate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Meloxicam sodium salt hydrate is a non-steroidal anti-inflammatory drug (NSAID) and cyclooxygenase-2 (COX-2) inhibitor that may be useful in treating inflammation and pain.

Chemical Structure

Meloxicam sodium salt hydrate
Meloxicam sodium salt hydrate
CAS#71125-39-8 (sodium hydrate)

Theoretical Analysis

MedKoo Cat#: 574779

Name: Meloxicam sodium salt hydrate

CAS#: 71125-39-8 (sodium hydrate)

Chemical Formula: C14H14N3NaO5S2

Exact Mass: 0.0000

Molecular Weight: 391.39

Elemental Analysis: C, 42.96; H, 3.61; N, 10.74; Na, 5.87; O, 20.44; S, 16.38

Price and Availability

Size Price Availability Quantity
100mg USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
71125-39-8 (sodium hydrate) 244241-53-0 (meglumine hydrate) 244241-52-9 (meglumine) 71125-38-7
Synonym
Meloxicam sodium salt hydrate; Metacam sodium salt hydrate, Mobec sodium salt hydrate, UH-AC 62XX sodium salt hydrate
IUPAC/Chemical Name
sodium 2-methyl-3-((5-methylthiazol-2-yl)carbamoyl)-2H-benzo[e][1,2]thiazin-4-olate 1,1-dioxide hydrate
InChi Key
IZBZAOZGNNQKPJ-UHFFFAOYSA-M
InChi Code
InChI=1S/C14H13N3O4S2.Na.H2O/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2;;/h3-7,18H,1-2H3,(H,15,16,19);;1H2/q;+1;/p-1
SMILES Code
[O-]C(C1=CC=CC=C12)=C(C(NC3=NC=C(C)S3)=O)N(C)S2(=O)=O.[H]O[H].[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Meloxicam sodium is a non-steroidal anti-inflammatory agent, inhibits COX activity, with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively.
In vitro activity:
In the current study, the in vitro effects of low-dose meloxicam (0.25 µg/ml) on CF41.Mg canine mammary carcinoma cells were evaluated. Cell migration and invasion were significantly reduced following treatment with meloxicam. These results indicate that 0.25 µg/ml meloxicam reduces cell migration and invasion, in part through modulating MMP-2 and β-catenin expression. Reference: Oncol Lett. 2017 Aug;14(2):2198-2206. https://pubmed.ncbi.nlm.nih.gov/28781660/
In vivo activity:
In a 2-period cross-over study, synovitis was induced at T = 0 h in the L or R intercarpal joint of 6 horses by intraarticular injection of 0.5 ng lipopolysaccharide (LPS). Horses received once daily meloxicam (0.6 mg/kg bwt per os) or placebo starting at post injection hour (PIH) 2, and clinical evaluations as well as blood and synovial fluid (SF) sampling were performed at PIH 0, 8, 24 and 168. Meloxicam caused a significant reduction in lameness at PIH 8 and 24 and tended to reduce effusion. In addition, meloxicam significantly suppressed SF prostaglandin E2 and substance P release at PIH 8 and bradykinin at PIH 24 compared to placebo treatment. Reference: Equine Vet J. 2009 Sep;41(7):693-9. https://pubmed.ncbi.nlm.nih.gov/19927589/

Preparing Stock Solutions

The following data is based on the product molecular weight 391.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Iturriaga MP, Paredes R, Arias JI, Torres CG. Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett. 2017 Aug;14(2):2198-2206. doi: 10.3892/ol.2017.6400. Epub 2017 Jun 16. PMID: 28781660; PMCID: PMC5530185. 2. Naruse T, Nishida Y, Hosono K, Ishiguro N. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis. 2006 Mar;27(3):584-92. doi: 10.1093/carcin/bgi240. Epub 2005 Oct 11. PMID: 16219634. 3. de Grauw JC, van de Lest CH, Brama PA, Rambags BP, van Weeren PR. In vivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis. Equine Vet J. 2009 Sep;41(7):693-9. doi: 10.2746/042516409x436286. PMID: 19927589. 4. Jones CJ, Streppa HK, Harmon BG, Budsberg SC. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs. Am J Vet Res. 2002 Nov;63(11):1527-31. doi: 10.2460/ajvr.2002.63.1527. PMID: 12428662.
In vitro protocol:
1. Iturriaga MP, Paredes R, Arias JI, Torres CG. Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett. 2017 Aug;14(2):2198-2206. doi: 10.3892/ol.2017.6400. Epub 2017 Jun 16. PMID: 28781660; PMCID: PMC5530185. 2. Naruse T, Nishida Y, Hosono K, Ishiguro N. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis. 2006 Mar;27(3):584-92. doi: 10.1093/carcin/bgi240. Epub 2005 Oct 11. PMID: 16219634.
In vivo protocol:
1. de Grauw JC, van de Lest CH, Brama PA, Rambags BP, van Weeren PR. In vivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis. Equine Vet J. 2009 Sep;41(7):693-9. doi: 10.2746/042516409x436286. PMID: 19927589. 2. Jones CJ, Streppa HK, Harmon BG, Budsberg SC. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs. Am J Vet Res. 2002 Nov;63(11):1527-31. doi: 10.2460/ajvr.2002.63.1527. PMID: 12428662.
1. Photophysical studies of oxicam group of NSAIDs: piroxicam, meloxicam and tenoxicam Banerjee R, et al. Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy 59(6), 1213-1222, (2003) 2. Cyclooxygenase-2 enzyme inhibitors: place in therapy. Noble SL, et al. Am. Fam. Physician. 61(12), 3669-3676, (2000)